Abstract

A simple and accurate method for determining levels of 4-([3,4-(methylenedioxy)benzyl]amino)-6,7,8-trimethoxyquinazoline, a novel cyclic GMP phosphodiesterase inhibitor, in dog plasma was developed. This method involves extraction with diethyl ether and reversed-phase high-performance liquid chromatography with ultraviolet detection. Regression analysis showed that the method was linear over the range 1.0-1000 ng/ml. The method was employed for the analysis of plasma samples in a preliminary pharmacokinetic study in beagle dogs.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.